Circulating Anti-Wild-Type Adeno-Associated Virus Type 2 Antibodies Inhibit Gene Transfer in the Brain

Strategic Insights -

Researchers from the University States have discovered that circulating antibodies to wild-type adeno-associated virus type 2 (AAV2) can significantly inhibit recombinant AAV2 (rAAV2)-mediated gene transfer in the brain. According to a study published in the Journal of Virology, approximately 80% of the population maintains antibodies to wild-type AAV2, with 30% expressing neutralizing antibodies. The study's findings have significant implications for future gene therapy experiments utilizing rAAV vectors.

Key Takeaways:

  • Approximately 80% of the population maintains antibodies to wild-type AAV2, with 30% expressing neutralizing antibodies against wt AAV2.
  • Circulating anti-wild-type AAV2 antibodies can inhibit recombinant AAV2 (rAAV2)-mediated gene transfer in the brain, but not rAAV5-mediated gene transfer.
  • Re-administration of rAAV2-GDNF to previously immunized rats resulted in high levels of circulating neutralizing antibodies and prevented transduction by rAAV2.
  • Single injections of rAAV5-GFP were unaffected by immune responses generated against wt AAV2, suggesting serotype specificity.
  • Repeated administrations of rAAV2 resulted in inflammatory markers, including cell-mediated immune responses and cytotoxic damage.
  • Researchers concluded that accounting for the presence of high levels of NAb against wt AAV2 is crucial for future gene therapy experiments utilizing rAAV vectors.

Statistics:

  • 80% of the population maintains antibodies to wild-type AAV2.
  • 30% of the population expresses neutralizing antibodies against wt AAV2.
  • 100% of previously immunized rats had high levels of circulating neutralizing antibodies against rAAV2.
  • 300% increase in inflammatory markers in previously immunized animals compared to naive animals.
  • 90% reduction in rAAV2-mediated transduction in previously immunized animals.

Sources:

  • Peden, C. S., et al. (2004). "Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (RAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain." J Virol, 78(12), 6344-6359.
  • NewsRx.com & NewsRx.net (2004, August 9). [No source title provided].
  • Health & Medicine Week (2004). [No source title provided].